诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件至 [email protected] 告知您的需求和 联 系方式，并在 邮 件中附上您的 ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

To report an adverse event or any drug related issues concerning Novartis medicinal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event.

Report side effects What is a side effect? A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment ...

April 26, 2023 Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities ...

Radioligand therapy explained RLTs combine a targeting compound, the ligand, that binds to a specific marker, with a radioisotope. The ligand directs the radioisotope to the target cancer cells ...

Metastatic prostate cancer has a 5-year survival rate of less than 30% 3; mCRPC patients who progress on multiple lines of therapy have limited treatment options FDA approval was based on pivotal ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise ...

The digital press release with multimedia content can be accessed here: Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta ® ...

Team Leader Quality Operations Regular, Full time Innovative Medicines India Hyderabad (Office) Mag 19, 2025 Specialist/Analyst - Supplier Quality Management Regular, Full time Innovative Medicines ...